RX
Recursion Pharmaceuticals
RXRX · NASDAQ
$3.63 +6.45% (+$0.22)
1M +12.73%
Market Cap $1.80B
P/E Ratio -
Div. Yield -
ROE 50.41%
Piotroski F-Score Weak
3/9Valuation
44 /100
Fair P/S 32.90x
P/B 1.97x
P/E N/A
Growth
100 /100
Growing Rev. growth 23.46%
Book val. growth 32.53%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 46.66%
Net margin 945.92%
Op. margin 991.72%
Quality
1 /100
Poor ROIC 48.34%
ROE 50.41%
ROA 42.79%
Debt
69 /100
Low Debt/Equity 0.07x
Current ratio 5.03x
Int. coverage -350.41x
Stability
75 /100
Stable Beta 1.07x
Rev. volatility 12.06%
EPS volatility 15.90%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o RXRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Najat Khan
Employees
600
Headquarters
Salt Lake City
Nadchodzące wydarzenia
04 LIS
Earnings
Upcoming earnings report